中国大陆地区Fonsecaea临床分离株的体外抗真菌药物敏感性特征

中国真菌学杂志　 2022, Vol. 17 　Issue (2): 132-136.

中国大陆地区Fonsecaea临床分离株的体外抗真菌药物敏感性特征

王会伟^1,2, 姜伟伟^1,2, 徐媛^1,2,3, 李颖芳^1,2,4, 李航^1,2, 朱信霖^1,2, 陈天杨^1,2, 王启龙⁵, 陈敏^1,2, 潘炜华^1,2, 廖万清^1,2

1. 海军军医大学上海长征医院皮肤科, 上海 200003;
2. 上海市医学真菌分子生物学重点实验室, 上海 200003;
3. 杭州市第三人民医院皮肤科, 杭州 310009;
4. 上海市皮肤病医院皮肤科, 上海 200443;
5. 69218部队医院, 喀什 844799

收稿日期:2022-03-30 出版日期:2022-04-28 发布日期:2022-05-07
通讯作者: 潘炜华,E-mail:panweihua9@sina.com E-mail:panweihua9@sina.com
作者简介:王会伟,男(汉族),硕士研究生在读.E-mail:qq2918473747@163.com;姜伟伟:男(汉族),硕士,主治医师.E-mail:914384879@qq.com
基金资助:
国家自然重点项目“中国人群高发的难治性暗色真菌感染的生态学和进化起源研究”（81720108026）

Antifungal drug susceptibility of Fonsecaea spp.

WANG Huiwei^1,2, JIANG Weiwei^1,2, XU yuan^1,2,3, LI Yingfang^1,2,4, LI Hang^1,2, ZHU Xinlin^1,2, CHEN Tianyang^1,2, Wang Qilong⁵, CHEN Min^1,2, PAN Weihua^1,2, LIAO Wanqing^1,2

1. Department of Dermatology, Shanghai Changzheng Hospital, Naval Military Medical University, Shanghai 200003, China;
2. Key Laboratory of Molecular Biology of Medical Fungi, Shanghai 200003, China;
3. Hangzhou Third People's Hospital, Hangzhou 310009, China;
4. Shanghai Dermatology Hospital, Shanghai 200443, China;
5. 69218 Military Hospital, Kashi 844799, China

Received:2022-03-30 Online:2022-04-28 Published:2022-05-07

摘要/Abstract

摘要： 目的通过体外药敏试验研究分离自我国的着色霉属（Fonsecaea spp.）临床菌株对抗真菌药物敏感性特征，为制定精准抗真菌治疗方案提供依据。方法采用美国临床实验室标准化委员会推荐的丝状菌标准的肉汤微量稀释法（CLSI M38-A2法），利用11 种临床抗真菌药物，对32株Fonsecaea spp.临床分离株进行的体外抗真菌敏感性测试，总结相关菌株的体外抗真菌药敏特征。同时，对迄今为止国内外83个已报道的Fonsecaea spp.病例的菌株药敏与临床特征进行系统性回顾分析。结果泊沙康唑（MIC₅₀=0.25 μg/mL，MIC₉₀=0.5 μg/mL）、艾沙康唑（MIC₅₀=0.25 μg/mL，MIC₉₀=0.5 μg/mL）、伏立康唑（MIC₅₀=0.125 μg/mL，MIC₉₀=0.25 μg/mL）等二代唑类抗真菌药对Fonsecaea spp.临床株的抗菌活性最高，而两性霉素B（MIC₅₀=4 μg/mL;MIC₉₀=8 μg/mL）、氟康唑（MIC₅₀=8 μg/mL，MIC₉₀>8 μg/mL）、棘白菌素类（MEC50=8 μg/mL，MEC₉₀>8 μg/mL）的抗菌活性较低。结论 Fonsecaea spp.3个常见的致病菌种对抗真菌药的敏感性和临床预后一致，优先推荐二代唑类药物（泊沙康唑、艾沙康唑、伏立康唑等）作为抗真菌治疗方案。有关Fonsecaea spp.临床分离菌株的体外联合药敏特征值得进一步研究。

关键词: 暗色真菌病, 着色霉, 体外药物敏感性试验, 抗真菌药物

Abstract: Objective To study Fonsecaea spp. strains isolated from China to understand the characteristics of antifungal drug susceptibility and to provide data basis for the development of precise antifungal drug regimens for dark fungal diseases caused by Fonsecaea spp. infections in China. Methods Using the broth microdilution method (CLSI M38-A2 method) recommended by the American Clinical Laboratory Standardization Committee for filamentous fungi, in this study, in vitro drug sensitivity tests were conducted on 32 clinical isolates of Fonsecaea spp. against 11 clinical antifungal drugs. We also systematically analyzed the drug sensitivity characteristics and clinical prognosis of 83 reported cases of Fonsecaea spp. infection in China and abroad. Results Fonsecaea spp. was most sensitive to the antifungal activity of second-generation azole antifungal drugs, including:posaconazole (MIC₅₀=0.25 μg/mL, MIC₉₀=0.5 μg/mL), esaconazole (MIC₅₀=0.25 μg/mL, MIC₉₀=0.5 μg/mL), voriconazole (MIC₅₀=0.125 μg/mL, MIC₉₀=0.25 μg/mL). While amphotericin B (MIC₅₀=4 μg/mL, MIC₉₀=8 μg/mL), fluconazole (MIC₅₀=8 μg/mL, MIC₉₀>8 μg/mL), and echinocandins (MEC₅₀=8 μg/mL, MEC₉₀>8 μg/mL) had lower antifungal activity against Fonsecaea spp. Conclusion For the antifungal treatment of Fonsecaea spp. infection, it is advisable to give preference to second-generation azoles (posaconazole, esaconazole, voriconazole, etc.). The in vitro combined drug sensitivity profile of clinical isolates of Fonsecaea spp. warrants further study.

Key words: dark fungal disease, Fonsecaea spp., in vitro drug sensitivity test, antifungal drugs

中图分类号:

R379.9

王会伟, 姜伟伟, 徐媛, 李颖芳, 李航, 朱信霖, 陈天杨, 王启龙, 陈敏, 潘炜华, 廖万清. 中国大陆地区Fonsecaea临床分离株的体外抗真菌药物敏感性特征[J]. 中国真菌学杂志, 2022, 17(2): 132-136.

WANG Huiwei, JIANG Weiwei, XU yuan, LI Yingfang, LI Hang, ZHU Xinlin, CHEN Tianyang, Wang Qilong, CHEN Min, PAN Weihua, LIAO Wanqing. Antifungal drug susceptibility of Fonsecaea spp.[J]. Chinese Journal of Mycology, 2022, 17(2): 132-136.

参考文献

[1] CHOWDHARY A, MEIS J F, GUARRO J, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis:diseases caused by black fungi[J]. Clin Microbiol Infect, 2014,20 (Suppl 3):47-75.
[2] SANTOS D W C L, DE AZEVEDO C D M P, VICENTE V A, et al. The global burden of chromoblastomycosis[J]. PLoS Negl Trop Dis, 2021,15(8):e9611.
[3] LAIQ S, Al YAQOOBI M, Al SAADI M, et al. Fonsecaea associated cerebral phaeohyphomycosis in a post-COVID-19 patient:A first case report[J]. Clin Infect Pract, 2022,13:100126. DOI:10.1016/j.clinpr.2021.100126.
[4] HELBIG S, THUERMER A, DENGL M, et al. Cerebral abscess by Fonsecaea monophora-the first case reported in Germany[J]. Open Forum Infect Dis, 2018,5(6):y129.
[5] ZHANG J, WU X, LI M, et al. Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo[Z]. Rev Inst Med Trop Sao Paulo,2019,61:e31. DOI:10.1590/S1678-9946201961031.
[6] DA SILVA HELLWIG A H, HEIDRICH D, ZANETTE R A, et al. In vitro susceptibility of chromoblastomycosis agents to antifungal drugs:A systematic review[J]. J Glob Antimicrob Resist, 2019,16:108-114. DOI:10.1016/j.jgar.2018.09.010.
[7] YANG Y, LI W, HUANG W, et al. Chromoblastomycosis caused by Fonsecaea:clinicopathology, susceptibility and molecular identification of seven consecutive cases in Southern China[J]. Clin Microbiol Infect, 2013,19(11):1023-1028.
[8] 朱信霖. 中国大陆地区赛多孢霉临床分离菌株的体外药敏测试及遗传多样性研究[D]. 中国人民解放军海军军医大学, 2021.
[9] 杨潇潇. 中国北方首例Fonsecaea nubica致着色芽生菌病及文献回顾[D]. 郑州大学, 2019.
[10] COELHO R A, BRITO-SANTOS F, FIGUEIREDO-CARVALHO M H G, et al. Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil.[J]. PLoS neglected tropical diseases, 2018,12(7):e6675.
[11] 杨亚波, 席丽艳. 着色芽生菌病治疗现状[J]. 实用皮肤病学杂志, 2012,5(3):159-161.

[1]	吴雨娴, 张旺喆麒, 徐洋, 柴晓云. 基于抗真菌药物的近红外荧光探针研究进展[J]. 中国真菌学杂志, 2022, 17(5): 431-434.
[2]	杨之辉, 李若瑜. 浅部真菌感染中的抗真菌药物治疗进展[J]. 中国真菌学杂志, 2022, 17(4): 339-348.
[3]	高路, 吕权真, 甄诚, 阎澜, 姜远英. 化学基因组学在抗真菌药物研究中的应用[J]. 中国真菌学杂志, 2022, 17(3): 235-240.
[4]	肖湘. 泌尿系念珠菌感染的抗真菌药物合理选用[J]. 中国真菌学杂志, 2022, 17(3): 241-243,264.
[5]	唐人杰, 王瑞娜, 王智, 刘海燕, 刘旭, 李红磊, 刘佳存, 张大志, 阎澜. 某院校学员浅部真菌病调查分析[J]. 中国真菌学杂志, 2022, 17(2): 120-123.
[6]	郁谨菡, 赵颖, 徐英春. 机会性致病真菌解脂耶氏酵母研究进展[J]. 中国真菌学杂志, 2022, 17(2): 168-172.
[7]	陈雪雯, 陈裕充, 温海. 部分新型外用唑类抗真菌药物治疗浅部真菌病的研究进展[J]. 中国真菌学杂志, 2022, 17(1): 55-58.
[8]	康烨, 王瑞娜, 阎澜. 抗真菌药物潜在靶点及化合物研究进展[J]. 中国真菌学杂志, 2021, 16(6): 414-419.
[9]	徐灵玲, 曾章锐, 丁银环, 杨葵. 川南地区侵袭性念珠菌感染流行病学及耐药性分析[J]. 中国真菌学杂志, 2021, 16(5): 319-325.
[10]	谭静文, 高志琴, 杨虹, 杨连娟. 国产泊沙康唑对生殖器来源念珠菌的体外药物敏感性研究[J]. 中国真菌学杂志, 2021, 16(5): 326-329,334.
[11]	张欠欠, 罗传玉, 陈嘉琪, 封小川. 白念珠菌感染现状及抗真菌药物研究进展[J]. 中国真菌学杂志, 2021, 16(5): 356-360.
[12]	李炳坤, 黄春阳, 李秀楹, 郑艳青, 潘开素, 廖万清, 曹存巍. 中国广西地区格特隐球菌菌种复合体的基因型分析[J]. 中国真菌学杂志, 2021, 16(2): 84-89.
[13]	李颖, 王贺, 张戈, 刘文静, 徐英春. Sensititre YeastOne显色药敏板与微量肉汤稀释法检测曲霉体外抗真菌药物敏感性的一致性研究[J]. 中国真菌学杂志, 2020, 15(4): 197-201.
[14]	郑晓丽, 陈官芝, 刘维达. 抗真菌药物的免疫调节作用[J]. 中国真菌学杂志, 2020, 15(3): 179-182.
[15]	赵德军, 杨淋. 贵州省某区域女性阴道念珠菌的菌种分布及耐药性分析[J]. 中国真菌学杂志, 2020, 15(2): 83-87.